论文部分内容阅读
[目的]了解我国政府实施科技政策对医药产业化学药品制造业、中成药制造业和生物、生化制品的制造业三个子行业科技活动影响的有效性。[方法]选取的是2002-2013年间医药产业中化学药品制造业、中成药制造业和生物、生化制品的制造业三个子行业的面板数据,对这些数据进行灰色关联系统分析,找出对这三个子行业各自最有效的激励政策。[结论]四项科技政策对化学药品制造业和生物、生化制品制造业的激励效果比较明显,有益于其科技活动能力的提升,对中成药制造业的激励效果稍差。其中,政府直接资助和政府融资担保政策对化学药品制造业的激励效果比对生物、生化制品制造业的激励效果更明显,而另外两项政策,即税收优惠和科技人才政策对生物生化制品制造业的激励效果比对化学药品制造业的激励效果更明显。[建议]政府应合理配置直接资助医药企业科技活动的经费,并加强监督管理;充分发挥好融资担保的职能作用,积极寻找支持医药企业增加科技活动投入的新途径。
[Objective] To understand the effectiveness of our government’s implementation of science and technology policies on the scientific and technological activities of the three sub-sectors of pharmaceutical manufacturing industry, proprietary Chinese medicine manufacturing industry and biological and biochemical products manufacturing industry. [Method] The panel data of three sub-sectors of manufacturing industry, traditional Chinese medicine manufacturing industry and biological and biochemical products manufacturing industry in the pharmaceutical industry from 2002 to 2013 were selected. The data were analyzed by gray relational system The three sub-sectors of their most effective incentive policies. [Conclusion] The four science and technology policies have a more obvious stimulating effect on the manufacturing of chemical drugs and biological and biochemical products manufacturing industries, which is beneficial to the improvement of their scientific and technological activities and less encouraging to the manufacturing of proprietary Chinese medicines. Among them, the direct government subsidies and government financing guarantee policies on the chemical industry manufacturing industry incentives than biological, chemical and biological products manufacturing incentive effect is more obvious, and the other two policies, namely, tax incentives and scientific and technological personnel policy on biological and chemical products manufacturing The incentive effect of the industry is more obvious than the incentive effect of the chemical manufacturing industry. [Proposal] The government should rationally allocate funding for scientific and technological activities directly funded pharmaceutical enterprises and strengthen supervision and management; give full play to the functions of financing guarantee, and actively look for new ways to support pharmaceutical enterprises to increase investment in science and technology activities.